Month: December 2020

VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) reports on the exploration program focused on the discovery of additional zones of higher grade mineralization within the Red Chris porphyry corridor.Eight drill holes totaling 12,652 metres have been completed since September. All drill holes intersected mineralization, except two that were dedicated geotechnical holes. A total of 99,018 metres of drilling from 77 drill holes has been completed since August 2019.At the East Zone, drilling has confirmed the potential for additional high grade mineralization south of the South Boundary Fault. This is a significant discovery that has the potential to expand the known area of the Red Chris Porphyry system as the South Boundary Fault has historically been assumed to define...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan” or the “Trust”) (TSX: REI.UN) today announced that it is issuing a notice of redemption to holders of its $250 million, 3.716% Series R senior unsecured debentures due December 13, 2021 (the “Debentures”). The Debentures will be redeemed in full on January 15, 2021 (the “Redemption Date”) in accordance with their terms.Pursuant to the terms of the trust indenture governing the Debentures, the Debentures will be redeemed at a redemption price equal to the greater of the “Canada Yield Price” and par, together in each case with accrued and unpaid interest to the Redemption Date. The “Canada Yield Price” calculated in accordance of the terms of the governing trust indenture,...

New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy, compared to placebo plus paclitaxel (as per AIPAC study)Fully funded by EOC Pharma, trial will involve approx. 152 patients across 20 clinical trial sites in ChinaFollows encouraging data from Immutep’s ongoing AIPAC Phase IIb study announced end of March and today and presented at the San Antonio Breast Cancer SymposiumGlobal webinar: 11 December at 8.30 am Australian Easter Daylight Time, details belowSydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese...

LAS VEGAS, NV, Dec. 09, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that “the Company has successfully Eliminated All Convertible Debt In Renegotiation Deal and Files 10K.”Meso announces that it has renegotiated the consolidation of all its convertible debt into non-convertible promissory notes and warrants. The renegotiation deal effectively saves the company from hundreds of millions of shares of possible dilution.“We are very pleased that we have been able to renegotiate our convertible debt,” said David Christensen, President and CEO. “Moving forward, the company will seek minimally dilutive sources of capital.”The company is...

PETALUMA, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm”), a leading independent branded hydroponics company with a comprehensive distribution platform, today announced the pricing of its initial public offering of 8,666,667 shares of common stock at a price to the public of $20.00 per share. In addition, Hydrofarm has granted the underwriters a 30-day option to purchase up to an additional 1,300,000 shares to cover over-allotments, if any. The shares are expected to begin trading on December 10, 2020 on the Nasdaq Global Select Market under the ticker symbol “HYFM.” The closing of the offering is expected to occur on December 14, 2020, subject to customary closing conditions.J.P. Morgan and Stifel are acting as lead book-running managers for the offering and as representatives of the underwriters....

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices located at 10170 Church Ranch Way, Suite 100, Westminster, CO 80021, approximately one-quarter mile from the previously noticed location. The meeting location change is due to the COVID-19 related unavailability of the previously noticed meeting location.Due to the COVID-19 pandemic, seating capacity will be limited to comply with guidelines promulgated by relevant public health authorities. Social distancing will be observed at all times during the meeting and each attendee will be required to wear a protective face covering. Should more participants want to join the meeting than...

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan” or the “Trust”) (TSX: REI.UN) today announced that it has agreed to issue $500 million principal amount of Series AD senior unsecured debentures (the “Debentures”). This issuance is RioCan’s second Green Bond offering.The Debentures are being offered on an agency basis by a syndicate of agents co-led by TD Securities, RBC Capital Markets, BMO Capital Markets, CIBC Capital Markets and Scotia Capital Inc. The Debentures will be sold at par, carry a coupon rate of 1.974% per annum and mature on June 15, 2026. Subject to customary closing conditions, the offering is expected to close on December 14, 2020. The Series AD Debentures are being issued as Green Bonds under the RioCan Green Bond Framework, which Sustainalytics, a global leader in providing...

At the close of business on 9 December 2020, Morten Opstad, chair of the board of IDEX Biometrics ASA, held the following voting rights in IDEX, for the purpose of the extraordinary general meeting on 15 December 2020:Total 258,443,610 shares or 31.1% of the share capital and votes, consisting of the following:Proxy to represent and vote for 147,524,365 shares or 17.8% of the share capital, including shares held by Mr Opstad and controlled entities.Proxy with voting instructions for 110,919,245 shares or 13.3% of the share capital.For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: + 47 918 00186Derek P. D’Antilio, Chief Financial OfficerE-mail: derek.dantilio@idexbiometrics.comTel: +1 978 273 1344About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading...

New York, NY, Dec. 09, 2020 (GLOBE NEWSWIRE) — Carney Technology Acquisition Corp. II (the “Company”) announced today that it priced its initial public offering of 35,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading tomorrow, Thursday, December 10, 2020, under the ticker symbol “CTAQU”. Each unit consists of one share of the Company’s Class A common stock and one-third of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade.  Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “CTAQ” and “CTAQW,” respectively.The...